Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

24 Nov 2021

Abstract excerpt

High-risk neuroblastoma (NB) often involves MYCN amplification as well as mutations in ALK. Currently, high-risk NB presents significant clinical challenges, and additional therapeutic options are needed. Oncogenes like MYCN and ALK result in increased replication stress in cancer cells, offering therapeutically exploitable options. We have pursued phosphoproteomic analyses highlighting ATR activity in ALK-driven...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Neuroblastoma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34819497
DOI: 10.1038/s41467-021-27057-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATR inhibition enables complete tumour regression in ALK-driven NB mouse modelsPMID 34819497Read ↗

ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionSemantic proximity Read ↗

ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionSemantic proximity Read ↗

ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCNSemantic proximity Read ↗

<i>MYCN</i> Amplification and <i>ATRX</i> Mutations are Incompatible in NeuroblastomaSemantic proximity Read ↗

MYCN amplification and ATRX mutations are incompatible in neuroblastoma.Semantic proximity Read ↗

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwaysSemantic proximity Read ↗

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read ↗

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma CellsSemantic proximity Read ↗

Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastomaSemantic proximity Read ↗

RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastomaSemantic proximity Read ↗

DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR InhibitionSemantic proximity Read ↗

DNA repair and replicative stress addiction in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.